Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
In brief
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams \[mg\]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years. Safety will be monitored throughout the study.
Key facts
- Study ID
- NCT05097989
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 100
- Starts
- 2022-01-14
- Expected to finish
- 2024-12-09
- Last updated by the study team
- 2025-10-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Loma Linda, California, United States
- Research Site — Northridge, California, United States
- Research Site — Gainesville, Florida, United States
- Research Site — Nampa, Idaho, United States
- Research Site — Des Moines, Iowa, United States
- Research Site — Kansas City, Missouri, United States
- Research Site — Albuquerque, New Mexico, United States
- Research Site — New York, New York, United States
- Research Site — Houston, Texas, United States
- Research Site — Ciudad de Buenos Aires, Argentina
- Research Site — Córdoba, Argentina
- Research Site — La Plata, Argentina
- Research Site — Rosario, Argentina
- Research Site — Clayton, Australia
- Research Site — Liverpool, Australia
- Research Site — Nedlands, Australia
- Research Site — Westmead, Australia
- Research Site — Belo Horizonte, Brazil
- Research Site — Curitiba, Brazil
- Research Site — Juiz de Fora, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — Salvador, Brazil
- Research Site — Guangzhou, China
- Research Site — Huntsville, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.